{"id":469338,"date":"2021-04-01T01:03:08","date_gmt":"2021-04-01T05:03:08","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=469338"},"modified":"2021-04-01T01:03:08","modified_gmt":"2021-04-01T05:03:08","slug":"celyad-oncology-announces-april-2021-conference-schedule","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/celyad-oncology-announces-april-2021-conference-schedule\/","title":{"rendered":"Celyad Oncology Announces April 2021 Conference Schedule"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">MONT-SAINT-GUIBERT, Belgium, April  01, 2021  (GLOBE NEWSWIRE) &#8212; Celyad Oncology SA (Euronext &amp; Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the company plans to participate at the following conferences in April 2021:<\/p>\n<p align=\"justify\">\n        <strong>Cell &amp; Gene Meeting on the Mediterranean<\/strong><br \/>\n        <br \/>Dates: April 6-9, 2021<br \/>Panel Title: Alternative Cell Solutions for Oncology<br \/>Panel Participant: Filippo Petti, CEO<br \/>Panel Webcast: Available on-demand through the conference <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=22kLQNNoF4jZgFU4VnrsltEchscrtGLl-e8qZo52HQS96-WGUPPbhCS2y2qSQvK0Cx6QxHkjeKC_IUhwtxzClw==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong>website<\/strong><\/a> starting Thursday, April 8<br \/>Company Presentation: Available on-demand through the conference <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=22kLQNNoF4jZgFU4VnrslgxsUViB1GeD0busfq4CcrTH2-OFtnXOOACjyPesfCkDf1Gwoe3H3MO9DOwNIi_-zA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong>website<\/strong><\/a> starting Tuesday, April 6<\/p>\n<p align=\"justify\">\n        <strong>2021 Virtual\u00a0Wells Fargo\u00a0Biotech\u00a0Corporate Access\u00a0Day<\/strong><br \/>\n        <br \/>Date: Thursday, April 8, 2021<\/p>\n<p align=\"justify\">\n        <strong>Kempen &amp; Co. Life Sciences Conference &#8211; European Cell, Gene &amp; RNA<\/strong><br \/>\n        <br \/>Date: Wednesday, April 28, 2021<\/p>\n<p align=\"justify\">\n        <strong>About Celyad Oncology SA<\/strong>\n      <\/p>\n<p align=\"justify\">Celyad Oncology SA is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company is developing a pipeline of allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidates for the treatment of both hematological malignancies and solid tumors. Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY. The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hjwTbyMhp0GRXkFKNNwNSxAf4typobJQnS41P6-CNAR61YyFvhUu_SFHy_9b2QpSxHypLqPyHeSxcIwPa_vSJQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong>www.celyad.com<\/strong><\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statement<\/strong>\n      <\/p>\n<p align=\"justify\">This release may contain forward-looking statements, within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may include statements regarding: the safety and clinical activity of Celyad Oncology\u2019s pipelines and financial condition, results of operation and business outlook. Forward-looking statements may involve known and unknown risks and uncertainties which might cause actual results, financial condition, performance or achievements of Celyad Oncology to differ materially from those expressed or implied by such forward-looking statements. Such risk and uncertainty includes the expected date of the Phase 1 trial initiation by year-end 2020, our development of additional shRNA-based allogenic candidates from our CYAD-200 series towards clinical trial, and the duration and severity of the COVID-19 pandemic and government measures implemented in response thereto. A further list and description of these risks, uncertainties and other risks can be found in Celyad Oncology\u2019s U.S. Securities and Exchange Commission (SEC) filings and reports, including in its Annual Report on Form 20-F filed with the SEC on March 25, 2020 and subsequent filings and reports by Celyad Oncology. These forward-looking statements speak only as of the date of publication of this document and Celyad Oncology\u2019s actual results may differ materially from those expressed or implied by these forward-looking statements. Celyad Oncology expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.<\/p>\n<p>\n        <strong>Investor and Media Contacts:<\/strong>\n      <\/p>\n<p>Sara Zelkovic<br \/>Communications &amp; Investor Relations Director<br \/>Celyad Oncology <br \/>investors@celyad.com<\/p>\n<p>Daniel Ferry<br \/>Managing Director<br \/>LifeSci Advisors, LLC<br \/>daniel@lifesciadvisors.com<\/p>\n<p>Source: Celyad Oncology SA<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwODc3MSM0MDk4MzA1IzUwMDA0NjU4Ng==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/fe326e2f-09f8-448d-b4d5-7b02830bc2bf\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MONT-SAINT-GUIBERT, Belgium, April 01, 2021 (GLOBE NEWSWIRE) &#8212; Celyad Oncology SA (Euronext &amp; Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the company plans to participate at the following conferences in April 2021: Cell &amp; Gene Meeting on the Mediterranean Dates: April 6-9, 2021Panel Title: Alternative Cell Solutions for OncologyPanel Participant: Filippo Petti, CEOPanel Webcast: Available on-demand through the conference website starting Thursday, April 8Company Presentation: Available on-demand through the conference website starting Tuesday, April 6 2021 Virtual\u00a0Wells Fargo\u00a0Biotech\u00a0Corporate Access\u00a0Day Date: Thursday, April 8, 2021 Kempen &amp; Co. Life Sciences Conference &#8211; European Cell, Gene &amp; RNA Date: Wednesday, April 28, 2021 &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/celyad-oncology-announces-april-2021-conference-schedule\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Celyad Oncology Announces April 2021 Conference Schedule&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-469338","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Celyad Oncology Announces April 2021 Conference Schedule - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/celyad-oncology-announces-april-2021-conference-schedule\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Celyad Oncology Announces April 2021 Conference Schedule - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MONT-SAINT-GUIBERT, Belgium, April 01, 2021 (GLOBE NEWSWIRE) &#8212; Celyad Oncology SA (Euronext &amp; Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the company plans to participate at the following conferences in April 2021: Cell &amp; Gene Meeting on the Mediterranean Dates: April 6-9, 2021Panel Title: Alternative Cell Solutions for OncologyPanel Participant: Filippo Petti, CEOPanel Webcast: Available on-demand through the conference website starting Thursday, April 8Company Presentation: Available on-demand through the conference website starting Tuesday, April 6 2021 Virtual\u00a0Wells Fargo\u00a0Biotech\u00a0Corporate Access\u00a0Day Date: Thursday, April 8, 2021 Kempen &amp; Co. Life Sciences Conference &#8211; European Cell, Gene &amp; RNA Date: Wednesday, April 28, 2021 &hellip; Continue reading &quot;Celyad Oncology Announces April 2021 Conference Schedule&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/celyad-oncology-announces-april-2021-conference-schedule\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-01T05:03:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwODc3MSM0MDk4MzA1IzUwMDA0NjU4Ng==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celyad-oncology-announces-april-2021-conference-schedule\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celyad-oncology-announces-april-2021-conference-schedule\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Celyad Oncology Announces April 2021 Conference Schedule\",\"datePublished\":\"2021-04-01T05:03:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celyad-oncology-announces-april-2021-conference-schedule\\\/\"},\"wordCount\":503,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celyad-oncology-announces-april-2021-conference-schedule\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwODc3MSM0MDk4MzA1IzUwMDA0NjU4Ng==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celyad-oncology-announces-april-2021-conference-schedule\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celyad-oncology-announces-april-2021-conference-schedule\\\/\",\"name\":\"Celyad Oncology Announces April 2021 Conference Schedule - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celyad-oncology-announces-april-2021-conference-schedule\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celyad-oncology-announces-april-2021-conference-schedule\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwODc3MSM0MDk4MzA1IzUwMDA0NjU4Ng==\",\"datePublished\":\"2021-04-01T05:03:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celyad-oncology-announces-april-2021-conference-schedule\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celyad-oncology-announces-april-2021-conference-schedule\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celyad-oncology-announces-april-2021-conference-schedule\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwODc3MSM0MDk4MzA1IzUwMDA0NjU4Ng==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwODc3MSM0MDk4MzA1IzUwMDA0NjU4Ng==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celyad-oncology-announces-april-2021-conference-schedule\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Celyad Oncology Announces April 2021 Conference Schedule\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Celyad Oncology Announces April 2021 Conference Schedule - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/celyad-oncology-announces-april-2021-conference-schedule\/","og_locale":"en_US","og_type":"article","og_title":"Celyad Oncology Announces April 2021 Conference Schedule - Market Newsdesk","og_description":"MONT-SAINT-GUIBERT, Belgium, April 01, 2021 (GLOBE NEWSWIRE) &#8212; Celyad Oncology SA (Euronext &amp; Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the company plans to participate at the following conferences in April 2021: Cell &amp; Gene Meeting on the Mediterranean Dates: April 6-9, 2021Panel Title: Alternative Cell Solutions for OncologyPanel Participant: Filippo Petti, CEOPanel Webcast: Available on-demand through the conference website starting Thursday, April 8Company Presentation: Available on-demand through the conference website starting Tuesday, April 6 2021 Virtual\u00a0Wells Fargo\u00a0Biotech\u00a0Corporate Access\u00a0Day Date: Thursday, April 8, 2021 Kempen &amp; Co. Life Sciences Conference &#8211; European Cell, Gene &amp; RNA Date: Wednesday, April 28, 2021 &hellip; Continue reading \"Celyad Oncology Announces April 2021 Conference Schedule\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/celyad-oncology-announces-april-2021-conference-schedule\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-01T05:03:08+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwODc3MSM0MDk4MzA1IzUwMDA0NjU4Ng==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celyad-oncology-announces-april-2021-conference-schedule\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celyad-oncology-announces-april-2021-conference-schedule\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Celyad Oncology Announces April 2021 Conference Schedule","datePublished":"2021-04-01T05:03:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celyad-oncology-announces-april-2021-conference-schedule\/"},"wordCount":503,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celyad-oncology-announces-april-2021-conference-schedule\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwODc3MSM0MDk4MzA1IzUwMDA0NjU4Ng==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celyad-oncology-announces-april-2021-conference-schedule\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/celyad-oncology-announces-april-2021-conference-schedule\/","name":"Celyad Oncology Announces April 2021 Conference Schedule - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celyad-oncology-announces-april-2021-conference-schedule\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celyad-oncology-announces-april-2021-conference-schedule\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwODc3MSM0MDk4MzA1IzUwMDA0NjU4Ng==","datePublished":"2021-04-01T05:03:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celyad-oncology-announces-april-2021-conference-schedule\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/celyad-oncology-announces-april-2021-conference-schedule\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celyad-oncology-announces-april-2021-conference-schedule\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwODc3MSM0MDk4MzA1IzUwMDA0NjU4Ng==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwODc3MSM0MDk4MzA1IzUwMDA0NjU4Ng=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celyad-oncology-announces-april-2021-conference-schedule\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Celyad Oncology Announces April 2021 Conference Schedule"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/469338","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=469338"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/469338\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=469338"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=469338"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=469338"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}